These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 20862394)
1. Targeting Wee1-like protein kinase to treat cancer. Stathis A; Oza A Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394 [TBL] [Abstract][Full Text] [Related]
2. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035 [TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655 [TBL] [Abstract][Full Text] [Related]
4. Cell cycle regulation by the Wee1 inhibitor PD0166285, pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. Hashimoto O; Shinkawa M; Torimura T; Nakamura T; Selvendiran K; Sakamoto M; Koga H; Ueno T; Sata M BMC Cancer; 2006 Dec; 6():292. PubMed ID: 17177986 [TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer. Geenen JJJ; Schellens JHM Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503 [TBL] [Abstract][Full Text] [Related]
6. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076 [TBL] [Abstract][Full Text] [Related]
7. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065 [TBL] [Abstract][Full Text] [Related]
8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
12. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation. Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012 [TBL] [Abstract][Full Text] [Related]
13. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy. Matheson CJ; Casalvieri KA; Backos DS; Reigan P ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531 [TBL] [Abstract][Full Text] [Related]
14. PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer. Jhuraney A; Woods NT; Wright G; Rix L; Kinose F; Kroeger JL; Remily-Wood E; Cress WD; Koomen JM; Brantley SG; Gray JE; Haura EB; Rix U; Monteiro AN Mol Cancer Ther; 2016 Jul; 15(7):1669-81. PubMed ID: 27196765 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. Smaill JB; Baker EN; Booth RJ; Bridges AJ; Dickson JM; Dobrusin EM; Ivanovic I; Kraker AJ; Lee HH; Lunney EA; Ortwine DF; Palmer BD; Quin J; Squire CJ; Thompson AM; Denny WA Eur J Med Chem; 2008 Jun; 43(6):1276-96. PubMed ID: 17869387 [TBL] [Abstract][Full Text] [Related]
16. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Leijen S; Beijnen JH; Schellens JH Curr Clin Pharmacol; 2010 Aug; 5(3):186-91. PubMed ID: 20406171 [TBL] [Abstract][Full Text] [Related]
17. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Indovina P; Marcelli E; Di Marzo D; Casini N; Forte IM; Giorgi F; Alfano L; Pentimalli F; Giordano A Cancer Biol Ther; 2014 Apr; 15(4):380-8. PubMed ID: 24365782 [TBL] [Abstract][Full Text] [Related]
18. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. Knight GL; Turnell AS; Roberts S J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322 [TBL] [Abstract][Full Text] [Related]
19. Wee1 kinase as a target for cancer therapy. Do K; Doroshow JH; Kummar S Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427 [TBL] [Abstract][Full Text] [Related]
20. Phosphorylation and inactivation of the mitotic inhibitor Wee1 by the nim1/cdr1 kinase. Parker LL; Walter SA; Young PG; Piwnica-Worms H Nature; 1993 Jun; 363(6431):736-8. PubMed ID: 8515817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]